Answer
In patients with moderate to severe plaque psoriasis, a single 210 mg subcutaneous dose of brodalumab increased midazolam exposure by 24%, a change that did not require dose adjustment of concomitant CYP3A4/3A5 substrates.
Sources for this answer
- Kyntheum 210 mg Solution for InjectionLeo Laboratories Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 7Document updated
Sources checked